Congestive heart failure during imatinib mesylate treatment

International Journal of Cardiology

Volumn 145, Issue 1, 2010, Pages 148-150

  Turrisi, Gina ^a   Montagnani, Francesco ^a   Grotti, Simone ^b   Marinozzi, Claudio ^c   Bolognese, Leonardo ^b   Fiorentini, Giammaria ^a  

^a S Giuseppe Hospital   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c S Giovanni di Dio Hospital   (Italy)

Author keywords

Cardiotoxicity; Comorbidities; Imatinib

Indexed keywords

DIURETIC AGENT; IMATINIB; CORTICOSTEROID; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM;

AGED; CARDIOTOXICITY; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEART PALPITATION; HUMAN; LETTER; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; TACHYPNEA; ABDOMINAL PAIN; ARTICLE; BODY MASS; CANCER GRADING; CARDIOVASCULAR RISK; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; ECHOGRAPHY; ELECTROCARDIOGRAM; FAMILY HISTORY; FOLLOW UP; HEART EJECTION FRACTION; HEART LEFT BUNDLE BRANCH BLOCK; HISTOPATHOLOGY; KIDNEY BIOPSY; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; SINUS RHYTHM; SINUS TACHYCARDIA; SUDDEN CARDIAC DEATH; SYMPTOM; SYSTOLIC HEART MURMUR; THORAX RADIOGRAPHY;

EID: 78049452908     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.07.006     Document Type: Article

References (12)

1. D.G. Savage, and K.H. Antman Imatinib mesylate - a new oral targeted therapy N Eng J Med 346 2002 683 693
2. L. Kerkela, R. Grazette, and R. Yacobi Cardiotoxicity of the cancer therapeutic agent Imatinib mesylate Nat Med 12 8 2006 908 916
3. G.D. Demetri, M. Von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Eng J Med 347 7 2002 472 480
4. C.D. Blanke, C. Rankin, and G.D. Demetri Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the c-kit receptor tyrosine kinase: S0033 J Clin Oncol 26 4 2008 626 632
5. J.Y. Blay, A. Le Cesne, and I. Ray-Coquard Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French sarcoma group J CLin Oncol 25 9 2007 1107 1113
6. M.S. Ribeiro, A.L. Marcolino, and H.N. Bittencourt An evaluation of the cardiotoxicity of imatinib mesylate Leuk Res 32 12 2008 1809 1814
7. P.J. Perik, B. Rikhof, and F.A. de Jong Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity Ann Oncol 19 2 2008 359 361
8. J. Verweij, P.G. Casali, and D. Kotasek Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005 Eur J Cancer 43 6 2007 974 978
9. M. Van Glabbeke, J. Verweij, and P.G. Casali Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG) Eur J Cancer 42 14 2006 2277 2285
10. E. Atallah, J.B. Durand, and H. Kantarjian Congestive heart failure is a rare event in patients receiving imatinib therapy Blood 110 4 2007 1233 1237
11. I.R. Judson Imatinib for patients with liver or kidney dysfunction: no need to modify the dose J Clin Oncol 26 4 2008 521 522
12. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150